SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as community members discuss its recent listing and availability on Phantom Wallet. The Solana-based token is being touted for its potential gains, with many highlighting its strong momentum and comparing it to other meme coins. Some users note its relative stability amidst broader market volatility.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin $CAW, also known as crow with knife, is trending as the community buzzes about its multichain presence across Solana, BSC, CRO, and ETH, plus its deflationary mechanism. Community members highlight its organic growth and partnerships, while also mentioning staking opportunities may be coming.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the community rallies behind it as the top memecoin on Bitcoin, emphasizing its fair launch and strong community-driven nature. Discussions highlight its potential to outperform other memecoins and its unique position within the Bitcoin ecosystem. Community members are actively promoting its listing on major exchanges and emphasizing its potential for significant growth.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending due to a collaboration with Kyowa Kirin to develop and commercialize ziftomenib, with the community debating the deal's long-term impact despite a recent milestone payment. Discussions also involve comparing Kura's safety profile to competitors like $SNDX and anticipating potential FDA approval, with some speculating on a possible buyout. Bullish sentiment stems from ziftomenib's potential in treating acute myeloid leukemia and the company's strong cash position.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst discussions on tariffs, CPI, and their potential impact, with community members debating whether previous losses have been recovered adequately. Chatter includes short interest, potential revenue beats, and forward-looking market valuation. The stock is also reacting to broader market forces like gold price fluctuations and sector-specific news from competitors.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is buzzing as Bitcoin flirts with all-time highs, driven by potential regulatory shifts and growing institutional interest. Community members are closely watching key resistance levels and debating whether Bitcoin's surge will continue or if a correction is on the horizon. The focus remains on Bitcoin's potential as both a safe haven and a growth asset amid economic uncertainty.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community debates its potential to break key resistance levels amid general market volatility, with some expressing frustration over its price action relative to Bitcoin and Binance Coin. There's also buzz around the coin's association with memecoins and upcoming catalysts like potential ETF approval and new partnerships for the Cronos chain. Community members are weighing the potential impact of these developments on CRO's price.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid anticipation for its Super App release and upcoming listings on major exchanges like Coinbase and Binance. The community is bullish, drawing comparisons to XRP and highlighting potential NBA and NHL sponsorships. Discussions also involve the project's utility in payroll and staking rewards through Uphold.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to its licensing deal with Vanqua Bio for an oral C5aR1 antagonist, signaling renewed interest in the C5aR pathway; the community is actively discussing the implications of this deal for InflaRx ($IFRX) and other companies in the sector. Discussions involve speculation on potential revenue and the competitive landscape. Also of interest are Biogen's earnings, drug pipeline, and potential for growth.

Teledyne Technologies, Inc. engages in the provision of electronic and communication products for wireless and satellite systems. It operates through the following business segments: Instrumentation, Digital Imaging, Aerospace and Defense Electronics, and Engineered Systems. The Instrumentation segment provides monitoring and control instruments for marine, environmental, industrial, and other applications, and electronic test and measurement equipment. The Digital Imaging segment includes high-performance sensors, cameras, and systems within the visible, infrared, ultraviolet, and X-ray spectra. The Aerospace and Defense Electronics segment offers electronic components and subsystems, data acquisition and communications components and equipment, harsh environment interconnects, and general aviation batteries. The Engineered Systems segment consists of systems engineering, integration and advanced technology development, and complex manufacturing solutions. The company was founded in 1960 and is headquartered in Thousand Oaks, CA.

Teledyne Technologies Inc

Teledyne Technologies ($TDY) is trending due to recent analyst activity, including price target adjustments, and discussions around its growth strategies and performance in the defense and aerospace sectors. The community is focused on the company's potential in areas like drones and AI, as well as its recent earnings and contract wins, with some expressing disappointment in the stock's price movement despite positive news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the...

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on...

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation...

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor Reports Third Quarter 2024 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for...

Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Xencor Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.71	--	--	N/A
Q2 '25	-$0.72	-$0.41	43.04%	BEAT
Q1 '25	-$0.58	-$0.66	-13.28%	MISSED
Q4 '24	-$0.78	-$0.62	20.92%	BEAT
Q3 '24	-$0.98	-$0.71	27.65%	BEAT

XNCR
Xencor Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest XNCR News

XNCRXencor Inc